about
Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neckComparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology referencePrognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapyPerformance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomyAccuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathologyQuantification of Tumor Oxygenation Based on FMISO PET: Influence of Location and Oxygen Level of the Well-Oxygenated Reference RegionOutcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung CancerProstate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
P50
Q36143844-9F9A0738-8E3A-4536-880E-AC405AD9E74AQ37541876-5B0DA232-A7FF-4E8B-9711-6DED471F7BA4Q38567364-EFCAA2F7-730E-4BF6-B4C9-5D38ABA221D8Q39424295-AC27C52B-5143-482F-84D0-77B8E9F65D5DQ64265749-1C09553C-EDBD-47D7-B678-6D16B8FD9082Q90373559-5CC9F0F2-5DFF-4A51-BAAC-2F1E06AA63D1Q90655981-357CD88E-7ED2-4751-8617-1826075862A8Q92143601-7901A390-B3B4-408F-92A7-AE6830801ADEQ92361182-1D2EB500-4D8D-41AE-9297-3165177FF1AAQ92461774-14F6297B-169B-4BC3-9F97-D261B13CDFBDQ93179338-4AADB2FC-5DC8-464D-9666-88A617B099BB
P50
description
researcher (ORCID 0000-0002-9106-2519)
@en
wetenschapper
@nl
name
Michael Mix
@en
Michael Mix
@nl
type
label
Michael Mix
@en
Michael Mix
@nl
prefLabel
Michael Mix
@en
Michael Mix
@nl
P31
P496
0000-0002-9106-2519